Adenovirus-mediated eukaryotic initiation factor 4E binding protein-1 in combination with rapamycin inhibits tumor growth of pancreatic ductal adenocarcinoma in vivo

International Journal of Oncology

Volumn 34, Issue 5, 2009, Pages 1231-1240

  Mishra, Roshan ^a   Miyamoto, Masaki ^a   Yoshioka, Tatsuya ^a   Ishikawa, Keidai ^a   Matsumura, Yoshiyuki ^a   Shoji, Yasuhito ^a   Ichinokawa, Kazuomi ^a   Itoh, Tommo ^b   Schichinohe, Toshiaki ^a   Hirano, Satoshi ^a   Kondo, Satoshi ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

Author keywords

eIF4E; Pancreatic ductal adenocarcinoma; Rapamycin; Translation initiation facto; Translation repressor protein 4E BP1

Indexed keywords

ADENOVIRUS VECTOR; GREEN FLUORESCENT PROTEIN; INITIATION FACTOR 4E; INITIATION FACTOR 4E BINDING PROTEIN 1; RAPAMYCIN;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER STAGING; CELL PROLIFERATION; CONTROLLED STUDY; EMBRYO CELL; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREAS CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; STOMACH CANCER; TRANSGENE; VIRAL GENE DELIVERY SYSTEM;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADENOVIRIDAE; ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CARCINOMA, PANCREATIC DUCTAL; CELL PROLIFERATION; COMBINED MODALITY THERAPY; FEMALE; GENE THERAPY; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MIDDLE AGED; PANCREATIC NEOPLASMS; PHOSPHOPROTEINS; SIROLIMUS; TRANSDUCTION, GENETIC; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 67649438657     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000251     Document Type: Article

References (31)

1. Jemal A, Murray T, Ward T, et al: Cancer Statistics. CA Cancer J Clin 55: 10-30, 2005.
2. Kleef J, Michalski C, Friess H and Büchler MW: Pancreatic cancer: from bench to 5-year survival. Pancreas 33: 111-118, 2006.
3. Sonenberg N and Gingras AC: The mRNA 5′cap-binding protein eIF4E and control of cell growth. Curr Opin Cell Biol 10: 268-275, 1998.
4. Kerekatte V, Smiley K, Hu B, Smith A, Gelder F and De Benedetti A: The proto-oncogene/translation factor eIF4E: a survey of its expression in breast carcinomas. Int J Cancer 64: 27-31, 1995.
5. Li BDL, McDonald JC, Nassar R and De Benedetti A: Clinical outcome in stage I to III breast carcinoma and eIF4E over expression. Ann Surg 227: 756-763, 1998.
6. Nathan CO, Franklin S, Abreo FW, Nassar R, De Benedetti A and Glass J: Analysis of surgical margins with the molecular marker eIF4E: a prognostic factor in patients with head and neck cancer. J Clin Oncol 17: 2909-2914, 1999.
7. Franklin S, Pho T, Abreo FW, Nassar R, De Benedetti A, Stucker FJ and Nathan CO: Detection of the proto-oncogene eIF4E in larynx and hypopharynx cancers. Arch Otolaryngol 125: 177-182, 1999.
8. Chen CN, Hsieh FJ, Cheng YM, Lee PH and Chang KJ: Expression of eukaryotic initiation factor 4E in gastric adenocarcinoma and its association with clinical outcome. J Surg Oncol 86: 22-27, 2004.
9. Gingras AC, Gygi SP, Raught B, et al: Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism. Genes Dev 13: 1422-1437, 1999.
10. Vogelstein B and Kinzler KW: Cancer genes and the pathways they control. Nat Med 10: 789-799, 2004.
11. Adjei AA and Hidalgo M: Intracellular signal transduction pathway proteins as targets for cancer therapy. J Clin Oncol 23: 5386-5403, 2005.
12. De Benedetti A and Graff JR: eIF-4E expression and its role in malignancies and metastases. Oncogene 23: 3189-3199, 2004.
13. Schmelzle T and Hall MN: TOR, a central controller of cell growth. Cell 103: 253-262, 2000.
14. Huang S and Houghton PJ: Targeting mTOR signaling for cancer therapy. Curr Opin Pharmacol 3: 371-377, 2003.
15. Bjornsti MA and Houghton PJ: The TOR pathway: a target for cancer therapy. Nat Rev Cancer 4: 335-348, 2004.
16. Rubio-Viqueira B and Hidalgo M: Targeting mTOR for cancer treatment. Curr Opin Investig Drugs 7: 501-512, 2006.
17. Abraham RT and Gibbons JJ: The mammalian target of rapamycin signaling pathway: twist and turns in the road to cancer therapy. Clin Cancer Res 13: 3109-3114, 2007.
18. Rousseau D, Gingras AC, Pause A and Sonenberg N: The eIF4E-binding proteins 1 and 2 are negative regulators of cell growth. Oncogene 13: 2415-2420, 1996.
19. Martin G, Gansauge F, Schmid MR, Adler G and Seufferlein T: Regulation of cell growth and cyclin D1 expression by the constitutively active FRAP-p70s6k pathway in human pancreatic cancer cells. Cancer Res 59: 3581-3587, 1999.
20. Dancey JE: Inhibitors of the mammalian target of rapamycin. Expert Opin Investig Drugs 14: 313-328, 2005.
21. Hidalgo M and Rowinsky EK: The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene 27: 6680-6686, 2000.
22. Huang S, Bjornsti MA and Houghton PJ: Rapamycin: mechanism of action and cellular resistance. Cancer Biol Ther 2: 222-232, 2003.
23. Shaw RJ and Cantley LC: Ras. PI(3)K and mTOR signaling controls tumor cell growth. Nature 441: 424-430, 2006.
24. Petroulakis E, Mamane Y, Le Bacquer O, Shahbazian D and Sonenberg N: mTOR signaling: implication for cancer and anticancer therapy. Br J Cancer 94: 195-199, 2007.
25. + tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma. Pancreas 28: 26-31, 2004.
26. He TC, Zhou S, Da Costa LT, Yu J, Kinzler KW and Vogelstein B: A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 95: 2509-2514, 1998.
27. Ugai H, Yamasaki T, Hirose M, et al: Purification of infectious adenovirus in two hours by ultracentrifugation and tangential flow filtration. Biochem Biophys Res Commun 331: 1053-1060, 2005.
28. Guba M, Breitenbuch P, Steinbauer M, et al: Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 8: 128-135, 2002.
29. Jacobson BA, Alter MD, Kratzke MG, et al: Repression of capdependent translation attenuates the transformed phenotype in non-small cell lung cancer both in vitro and in vivo. Cancer Res 66: 4256-4262, 2006.
30. Stephan S, Datta K, Wang E, et al: Effect of rapamycin alone and in combination with antiangiogenesis therapy in an orthotopic model of human pancreatic cancer. Clin Cancer Res 10: 6993-7000, 2004.
31. Ito D, Fujimoto K, Mori T, et al: In vivo antitumor effect of the mTOR inhibitor CCI-779 and gemcitabin in xenograft models of human pancreatic cancer. Int J Cancer 118: 2337-2343, 2006.